6/11 Drugs.com - Clinical Trials

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Drugs.com - Clinical Trials Presented at SLEEP 2009: New Controlled-Release Formulations of Proven Drug Being Developed for Middle-of-the-Night Awakening June 10, 2009 at 2:50 pm Advances in Sleep Research Help Speed Somnus Therapeutics' Development of Zaleplon-Based Sleep-Maintenance Treatment SEATTLE--(BUSINESS WIRE)--Jun 8, 2009 - Research sponsored by Somnus Therapeutics, Inc. demonstrates that new controlled-release... FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight June 10, 2009 at 2:42 pm ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions... Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function June 10, 2009 at 2:06 pm Three Oral Presentations to be Given at ENDO 09, the Endocrine Society's 91st Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 10, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth... Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride June 10, 2009 at 2:05 pm NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically... InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting June 10, 2009 at 2:03 pm LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides... Avid Radiopharmaceuticals to Present Clinical Trial Advances in Molecular Imaging of Alzheimer's Disease, Parkinson's Disease and Diabetes June 10, 2009 at 12:55 pm Data to be presented at the 56th Annual Society of Nuclear Medicine Meeting PHILADELPHIA--(BUSINESS WIRE)--Jun 10, 2009 - Avid Radiopharmaceuticals, Inc. announced today that three oral presentations and four poster presentations will be made about... Nutra Pharma Announces Study Showing RPI-78 More Effective than Morphine in the Treatment of Moderate to Severe Pain June 10, 2009 at 12:45 pm A ReceptoPharm Study Published in Toxicon, the Official Journal of the International Society on Toxinology, Shows That Their Leading Drug Candidate, RPI-78, is More Effective Than Morphine in the Treatment of Pain BOCA RATON, Fla.--(BUSINESS... Response Rates of 58-74% With Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL June 10, 2009 at 9:59 am Overview of 11 peer review publications presented in 'Future Oncology'   SEATTLE, June 08, 2009 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II... Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis June 10, 2009 at 8:53 am Amends Ester Neurosciences Acquisition Agreement DUBLIN--(BUSINESS WIRE)--Jun 10, 2009 - Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical...   This email was sent to skripayura.drugsnews@blogger.com.  Create Your Account Don't want to receive this feed any longer? Unsubscribe here.